Heather Berger, Ph.D., is a Venture Partner at Forge Life Science Partners, a boutique life science investment fund. Prior to this, she served as Chief Business Officer of Iolyx Therapeutics and was previously principal at SR One and at Sofinnova Investments, concentrating on novel opportunities across therapeutic areas, serving on the boards of Second Genome and Entasis Therapeutics (ETTX). Previously, Dr. Berger was an equity research analyst at Wedbush Securities and an associate at JMP Securities. Dr. Berger was formerly a chemist at the Astellas Research Institute and adjunct faculty at the Feinberg Northwestern School of Medicine. Dr. Berger received her Ph.D. in chemistry at Northwestern University, MSc. in organic chemistry at the Weizmann Institute of Science and her B.S. from Tufts University.